Cargando…

High expression of eIF3d is associated with poor prognosis in patients with gastric cancer

BACKGROUND: Eukaryotic initiation factor 3 subunit d (eIF3d) is the largest subunit of eIF3, which is shown to promote protein synthesis in cancer cells. Increased expression of eIF3d has been shown in some types of cancers, but has not been previously studied in gastric cancer (GC). Thus, the aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jiaqi, Wang, Xuefei, Cai, Jianhua, Wang, Wei, Qin, Xinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661832/
https://www.ncbi.nlm.nih.gov/pubmed/29123423
http://dx.doi.org/10.2147/CMAR.S142324
_version_ 1783274552481021952
author He, Jiaqi
Wang, Xuefei
Cai, Jianhua
Wang, Wei
Qin, Xinyu
author_facet He, Jiaqi
Wang, Xuefei
Cai, Jianhua
Wang, Wei
Qin, Xinyu
author_sort He, Jiaqi
collection PubMed
description BACKGROUND: Eukaryotic initiation factor 3 subunit d (eIF3d) is the largest subunit of eIF3, which is shown to promote protein synthesis in cancer cells. Increased expression of eIF3d has been shown in some types of cancers, but has not been previously studied in gastric cancer (GC). Thus, the aim of this study was to analyze eIF3d expression in GC. PATIENTS AND METHODS: Expression of eIF3d was detected by immunohistochemistry in GC tissues and adjacent noncancerous (ANC) tissues. Samples were obtained from 210 patients with GC who had received curative gastrectomy. Clinicopathological features and survival rate were also analyzed. RESULTS: Expression rates of eIF3d in GC and ANC were 45.2% and 21.0%, respectively. High expression of eIF3d protein was significantly related to tumor stage, as determined by lymph node metastasis and depth of invasion (p<0.05). The Kaplan–Meier survival curves showed that patients with high eIF3d expression had a significantly poor overall survival (p=0.005). Multivariate Cox regression analyses showed that the level of eIF3d was an independent predictive factor of poor prognosis for GC (p=0.017). CONCLUSION: Expression of eIF3d was upregulated in GC. High expression of eIF3d was determined as an independent poor prognostic factor in GC. It is suggested that eIF3d could be a good biomarker in GC.
format Online
Article
Text
id pubmed-5661832
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56618322017-11-09 High expression of eIF3d is associated with poor prognosis in patients with gastric cancer He, Jiaqi Wang, Xuefei Cai, Jianhua Wang, Wei Qin, Xinyu Cancer Manag Res Original Research BACKGROUND: Eukaryotic initiation factor 3 subunit d (eIF3d) is the largest subunit of eIF3, which is shown to promote protein synthesis in cancer cells. Increased expression of eIF3d has been shown in some types of cancers, but has not been previously studied in gastric cancer (GC). Thus, the aim of this study was to analyze eIF3d expression in GC. PATIENTS AND METHODS: Expression of eIF3d was detected by immunohistochemistry in GC tissues and adjacent noncancerous (ANC) tissues. Samples were obtained from 210 patients with GC who had received curative gastrectomy. Clinicopathological features and survival rate were also analyzed. RESULTS: Expression rates of eIF3d in GC and ANC were 45.2% and 21.0%, respectively. High expression of eIF3d protein was significantly related to tumor stage, as determined by lymph node metastasis and depth of invasion (p<0.05). The Kaplan–Meier survival curves showed that patients with high eIF3d expression had a significantly poor overall survival (p=0.005). Multivariate Cox regression analyses showed that the level of eIF3d was an independent predictive factor of poor prognosis for GC (p=0.017). CONCLUSION: Expression of eIF3d was upregulated in GC. High expression of eIF3d was determined as an independent poor prognostic factor in GC. It is suggested that eIF3d could be a good biomarker in GC. Dove Medical Press 2017-10-25 /pmc/articles/PMC5661832/ /pubmed/29123423 http://dx.doi.org/10.2147/CMAR.S142324 Text en © 2017 He et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
He, Jiaqi
Wang, Xuefei
Cai, Jianhua
Wang, Wei
Qin, Xinyu
High expression of eIF3d is associated with poor prognosis in patients with gastric cancer
title High expression of eIF3d is associated with poor prognosis in patients with gastric cancer
title_full High expression of eIF3d is associated with poor prognosis in patients with gastric cancer
title_fullStr High expression of eIF3d is associated with poor prognosis in patients with gastric cancer
title_full_unstemmed High expression of eIF3d is associated with poor prognosis in patients with gastric cancer
title_short High expression of eIF3d is associated with poor prognosis in patients with gastric cancer
title_sort high expression of eif3d is associated with poor prognosis in patients with gastric cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661832/
https://www.ncbi.nlm.nih.gov/pubmed/29123423
http://dx.doi.org/10.2147/CMAR.S142324
work_keys_str_mv AT hejiaqi highexpressionofeif3disassociatedwithpoorprognosisinpatientswithgastriccancer
AT wangxuefei highexpressionofeif3disassociatedwithpoorprognosisinpatientswithgastriccancer
AT caijianhua highexpressionofeif3disassociatedwithpoorprognosisinpatientswithgastriccancer
AT wangwei highexpressionofeif3disassociatedwithpoorprognosisinpatientswithgastriccancer
AT qinxinyu highexpressionofeif3disassociatedwithpoorprognosisinpatientswithgastriccancer